Cervical carcinomas overexpress human trophoblast cell-surface marker (Trop-2) and are highly sensitive to immunotherapy with hRS7, a humanized monoclonal anti-Trop-2 antibody

This publication has 21 references indexed in Scilit:

• Uterine serous papillary carcinomas overexpress human trophoblast‐cell‐surface marker (trop‐2) and are highly sensitive to immunotherapy with hRS7, a humanized anti‐trop‐2 monoclonal antibody
  Cancer, 2011
• Trop2 expression contributes to tumor pathogenesis by activating the ERK MAPK pathway
  Molecular Cancer, 2010
• Trop-2 overexpression as an independent marker for poor overall survival in ovarian carcinoma patients
  European Journal of Cancer, 2010
• Trop2: A possible therapeutic target for late stage epithelial carcinomas
  Biochimica et Biophysica Acta (BBA) - Reviews on Cancer, 2009
• High expression of TROP2 correlates with poor prognosis in pancreatic cancer
  British Journal of Cancer, 2008
• TROP2: a novel prognostic marker in squamous cell carcinoma of the oral cavity
  Laboratory Investigation, 2008
• Serological identification of TROP2 by recombinant cDNA expression cloning using sera of patients with esophageal squamous cell carcinoma
  International Journal of Cancer, 2004
• Randomised study of radical surgery versus radiotherapy for stage Ib-IIa cervical cancer
  The Lancet, 1997
• Specificity and properties of MAb RS7‐3G11 and the antigen defined by this pancarcinoma monoclonal antibody
  International Journal of Cancer, 1993
• Biochemical Characterization of Trop-2, a Cell Surface Molecule Expressed by Human Carcinomas: Formal Proof that the Monoclonal Antibodies T16 and MOv-16 Recognize Trop-2
  Hybridoma, 1992